{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:28:56Z","timestamp":1794011336576,"version":"4.8.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The escalating number of deaths related to opioid usage has intensified the pursuit of non-opioid alternatives for managing chronic pain. It's often observed that psychiatric comorbidities coexist in patients suffering from chronic pain. There are a variety of psychotropic medications that have demonstrated effectiveness in treating both psychiatric symptoms and pain. This systematic review and meta-analysis aim to assess the effectiveness of various psychiatric drugs in managing specific types of chronic pain, including fibromyalgia, neuropathic pain, and chronic low back pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search of five major databases was conducted through February 2023 to identify randomized controlled trials (RCTs) that met our inclusion criteria, focusing on outpatients Over 18 years of age with chronic pain. The study assessed the effectiveness of duloxetine, mirogabalin, pregabalin, gabapentin, and tricyclic antidepressants (TCAs), including serotonin-norepinephrine reuptake inhibitors (SNRIs), across various chronic pain conditions such as fibromyalgia, neuropathic pain, and chronic low back pain. The primary outcome measures included pain reduction, improvement in function, and quality of life. Of the 29 RCTs in the systematic review, 20 studies qualified for the meta-analysis. The analysis was stratified by pain type and treatment duration (short-term \u226414 weeks vs. long-term &amp;gt;14 weeks), using Hedge's g standardized mean differences and a random-effects model, along with sensitivity and subgroup analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall short-term intervention effect across all studies was significant (SMD \u22121.45, 95% CI \u22122.15 to \u22120.75,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), with considerable heterogeneity (I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200999%). For fibromyalgia, both duloxetine and mirogabalin demonstrated substantial efficacy with SMDs of \u22122.42 (95% CI \u22123.67 to \u22121.18,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.0001) and \u22122.10 (95% CI \u22123.28 to \u22120.92,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0005), respectively. Conversely, treatments for neuropathic pain and chronic low back pain, including those with amitriptyline and desipramine, did not show significant benefits. The effectiveness of gabapentin could not be conclusively determined due to limited representation in the data. Additionally, no consistent long-term benefits were observed for any of the medications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While the results of this study underscore the importance of exploring non-opioid alternatives for chronic pain management, particularly in light of the opioid crisis, it is crucial to interpret the findings carefully. Our analysis suggests that certain psychiatric medications, such Duloxetine and mirogabalin demonstrated significant short-term efficacy in fibromyalgia patients. However, their effectiveness in treating neuropathic pain and chronic low back pain was not statistically significant. Additionally, the effectiveness of gabapentin and other medications, such as pregabalin for neuropathic pain, could not be conclusively determined due to limited data and high study heterogeneity. No consistent long-term benefits were observed for any of the drugs studied, raising questions about their sustained efficacy in chronic pain management. These findings highlight the need for further research to understand better the role of psychiatric medications in managing specific chronic pain conditions without prematurely concluding that they are ineffective or unsuitable for these purposes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpain.2024.1398442","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T08:39:24Z","timestamp":1728549564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Non-opioid psychiatric medications for chronic pain: systematic review and meta-analysis"],"prefix":"10.3389","volume":"5","author":[{"given":"Shahana","family":"Ayub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Krishna","family":"Bachu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanli","family":"Parnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhi","family":"Bhivandkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasleen","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya","family":"Karlapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansini","family":"Kochhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oghenetega Esther","family":"Ayisire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloni","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikona","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavani Nagendra","family":"Papudesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palash Kumar","family":"Malo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoib","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"De Berardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","article-title":"Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis","volume":"156","author":"Vowles","year":"2015","journal-title":"Pain"},{"key":"B2","article-title":"Associations concerning Nonmedical Pain Reliefs Use and Initiation of Heroin Usage in the United Country","author":"Muhuri","year":""},{"key":"B3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1126\/science.aal2943","article-title":"Forecasting the opioid epidemic","volume":"354","author":"Burke","year":"2016","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e187621","DOI":"10.1001\/jamanetworkopen.2018.7621","article-title":"Prevention of prescription opioid misuse and projected overdose deaths in the United States","volume":"2","author":"Chen","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.15585\/mmwr.mm6734a2","article-title":"Opportunities to prevent overdose deaths involving prescription and illicit opioids, 11 states, July 2016\u2013June 2017","volume":"67","author":"Mattson","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.15585\/mmwr.mm7050e3","article-title":"Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls - United States, 2019\u20132020","volume":"70","author":"O'Donnell","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2023677","DOI":"10.1001\/jamanetworkopen.2020.23677","article-title":"Modeling mitigation strategies to reduce opioid-related morbidity and mortality in the U.S","volume":"3","author":"Ballreich","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e210001-e","DOI":"10.1001\/jamahealthforum.2021.0001","article-title":"CDC Warns of surge in drug overdose deaths during COVID-19","volume":"2","author":"Stephenson","year":"2021","journal-title":"JAMA Health Forum"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e2110452-e","DOI":"10.1001\/jamanetworkopen.2021.10452","article-title":"Drug overdose deaths before and after shelter-in-place orders during the COVID-19 pandemic in San Francisco","volume":"4","author":"Appa","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B10","article-title":"Overdose Deaths Surged In Pandemic, As More Drugs Were Laced With Fentanyl. NPR","author":"Mann","year":"2021"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/ajhp\/zxz105","article-title":"Medications for management of opioid use disorder","volume":"76","author":"Koehl","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"B12","article-title":"New AMA Substance Use & Pain Care Task Force urges action to help patients [press release]. AMA","year":"2021"},{"key":"B13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1136\/eb-2018-102877","article-title":"Non-opioid analgesia is as effective as opioid management in acute pain and supports a change in prescribing practice to help address the \u2018opioid epidemic\u2019","volume":"21","author":"Swift","year":"2018","journal-title":"Evid Based Nurs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1001\/jama.2017.16190","article-title":"Effect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department: a randomized clinical trial","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"key":"B15","volume-title":"SAMHSA\/CSAT Treatment Improvement Protocols. Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders","year":"2012"},{"key":"B16","first-page":"9","volume-title":"Pain Management","author":"Fenske","year":"2021"},{"key":"B17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13643-021-01599-4","article-title":"Efficacy, acceptability, and safety of antidepressants for low back pain: a systematic review and meta-analysis","volume":"10","author":"Ferraro","year":"2021","journal-title":"Syst Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"480","DOI":"10.7326\/M16-2458","article-title":"Systemic pharmacologic therapies for low back pain: a systematic review for an American college of physicians clinical practice guideline","volume":"166","author":"Chou","year":"2017","journal-title":"Ann Intern Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"514","DOI":"10.7326\/M16-2367","article-title":"Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American college of physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.23970\/AHRQEPCCER228","volume-title":"AHRQ Comparative Effectiveness Reviews. Nonopioid Pharmacologic Treatments for Chronic Pain","author":"McDonagh","year":"2020"},{"key":"B21","doi-asserted-by":"publisher","first-page":"Cd011735","DOI":"10.1002\/14651858.CD011735","article-title":"Selective serotonin reuptake inhibitors for fibromyalgia syndrome","volume":"2015","author":"Walitt","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.bja.2021.08.032","article-title":"Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors as adjuncts for postoperative pain management: systematic review and meta-analysis of randomised controlled trials","volume":"128","author":"Wang","year":"2022","journal-title":"Br J Anaesth"},{"key":"B23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"m4825","DOI":"10.1136\/bmj.m4825","article-title":"Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis","volume":"372","author":"Ferreira","year":"2021","journal-title":"Br Med J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1097\/j.pain.0000000000001622","article-title":"Beyond pain: can antidepressants improve depressive symptoms and quality of life in patients with neuropathic pain? A systematic review and meta-analysis","volume":"160","author":"Caruso","year":"2019","journal-title":"Pain"},{"key":"B26","doi-asserted-by":"publisher","first-page":"Cd009807","DOI":"10.1002\/14651858.CD009807","article-title":"Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome","volume":"4","author":"Tort","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.3899\/jrheum.110569","article-title":"An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia","volume":"38","author":"Pauer","year":"2011","journal-title":"J Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"R217","DOI":"10.1186\/ar4056","article-title":"A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia","volume":"14","author":"Ohta","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1185\/03007995.2014.928275","article-title":"Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study","volume":"30","author":"Arnold","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1080\/03007995.2019.1629757","article-title":"Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study","volume":"35","author":"Arnold","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"B32","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/AJP.0b013e3182510295","article-title":"Efficacy and safety of duloxetine 30\u2005mg\/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study","volume":"28","author":"Arnold","year":"2012","journal-title":"Clin J Pain"},{"key":"B33","doi-asserted-by":"publisher","first-page":"R86","DOI":"10.1186\/ar3359","article-title":"Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial","volume":"13","author":"Arnold","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12969-019-0325-6","article-title":"Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial","volume":"17","author":"Upadhyaya","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/AJP.0b013e31819be587","article-title":"A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia","volume":"25","author":"Chappell","year":"2009","journal-title":"Clin J Pain"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.pain.2014.05.027","article-title":"A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy","volume":"155","author":"Simpson","year":"2014","journal-title":"Pain"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.pain.2010.12.023","article-title":"Safety and efficacy of pregabalin in patients with central post-stroke pain","volume":"152","author":"Kim","year":"2011","journal-title":"Pain"},{"key":"B38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1212\/WNL.0b013e318281546b","article-title":"A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury","volume":"80","author":"Cardenas","year":"2013","journal-title":"Neurology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1464-5491.2010.03152.x","article-title":"Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial","volume":"28","author":"Satoh","year":"2011","journal-title":"Diabet Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.2337\/dc12-0656","article-title":"Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life","volume":"35","author":"Boyle","year":"2012","journal-title":"Diabetes Care"},{"key":"B41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/0253-7613.91867","article-title":"Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy","volume":"44","author":"Devi","year":"2012","journal-title":"Indian J Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/papr.12014","article-title":"A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy","volume":"13","author":"Rauck","year":"2013","journal-title":"Pain Pract"},{"key":"B43","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.2040-1124.2010.00073.x","article-title":"Superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in Japan","volume":"2","author":"Yasuda","year":"2011","journal-title":"J Diabetes Investig"},{"key":"B44","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/ijcp.12641","article-title":"Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. Placebo","volume":"69","author":"Gao","year":"2015","journal-title":"Int J Clin Pract"},{"key":"B45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/jdi.12361","article-title":"Efficacy and safety of 40\u2005mg or 60\u2005mg duloxetine in Japanese adults with diabetic neuropathic pain: results from a randomized, 52-week, open-label study","volume":"7","author":"Yasuda","year":"2016","journal-title":"J Diabetes Investig"},{"key":"B46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jns.2014.05.002","article-title":"An open labeled randomized controlled trial of pregabalin versus amitriptyline in chronic low backache","volume":"342","author":"Kalita","year":"2014","journal-title":"J Neurol Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1097\/j.pain.0000000000000554","article-title":"A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component","volume":"157","author":"Atkinson","year":"2016","journal-title":"Pain"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/j.1468-1331.2009.02648.x","article-title":"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain","volume":"16","author":"Skljarevski","year":"2009","journal-title":"Eur J Neurol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.clinthera.2014.02.009","article-title":"Onset of response with duloxetine treatment in patients with osteoarthritis knee pain and chronic low back pain: a post hoc analysis of placebo-controlled trials","volume":"36","author":"Williamson","year":"2014","journal-title":"Clin Ther"},{"key":"B50","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/ALN.0000000000000902","article-title":"Efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial","volume":"124","author":"Schukro","year":"2016","journal-title":"Anesthesiology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1097\/BRS.0000000000001707","article-title":"Randomized, double-blind, placebo-controlled phase III trial of duloxetine monotherapy in Japanese patients with chronic low back pain","volume":"41","author":"Konno","year":"2016","journal-title":"Spine (Phila Pa 1976)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamainternmed.2018.4222","article-title":"Efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial","volume":"178","author":"Urquhart","year":"2018","journal-title":"JAMA Intern Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/jcp.0b013e3180333ed5","article-title":"Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial","volume":"27","author":"Atkinson","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e0195776","DOI":"10.1371\/journal.pone.0195776","article-title":"Effect of single-dose imipramine on chronic low-back and experimental pain. A randomized controlled trial","volume":"13","author":"Schliessbach","year":"2018","journal-title":"PLoS One"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1097\/j.pain.0000000000001834","article-title":"A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain","volume":"161","author":"Gould","year":"2020","journal-title":"Pain"},{"key":"B56","volume-title":"Efficacy and Mechanism Evaluation. Gabapentin to Reduce Pain in Women Aged Between 18 and 50 Years with Chronic Pelvic Pain: The GaPP2 RCT","author":"Hewitt","year":"2020"},{"key":"B57","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(20)31693-7","article-title":"Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"396","author":"Horne","year":"2020","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1186\/s13063-016-1637-1","article-title":"Is low-dose amitriptyline effective in the management of chronic low back pain? Study protocol for a randomised controlled trial","volume":"17","author":"Urquhart","year":"2016","journal-title":"Trials"},{"key":"B59","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.2014.3266","article-title":"Fibromyalgia: a clinical review","volume":"311","author":"Clauw","year":"2014","journal-title":"Jama"},{"key":"B61","doi-asserted-by":"publisher","first-page":"15022","DOI":"10.1038\/nrdp.2015.22","article-title":"Fibromyalgia","volume":"1","author":"H\u00e4user","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B62","doi-asserted-by":"publisher","first-page":"Cd001703","DOI":"10.1002\/14651858.CD001703.pub3","article-title":"Antidepressants for non-specific low back pain","volume":"2008","author":"Urquhart","year":"2008","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2024.1398442\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T08:39:30Z","timestamp":1728549570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2024.1398442\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":62,"alternative-id":["10.3389\/fpain.2024.1398442"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2024.1398442","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"article-number":"1398442"}}